Hopkins' Joshua Sharfstein writes at JAMA Forum about how the Trump administration has been dealing with scientific evidence.
Johns Hopkins researchers added protein analysis to circulating tumor DNA testing to better detect early-stage pancreatic cancer.
Investigators retraced features contributing to Lyme disease spread by sequencing 146 Borrelia burgdorferi isolates collected in North America since the 1980s.
Using blood samples from 200 cancer patients, researchers showed that it is possible to find most early cancer cases with targeted error correction sequencing.
The company plans to develop tests for prostate cancer risk assessment, prostate cancer screening, and breast cancer screening.
The approach, published earlier this week in Nature Biomedical Engineering, uses long-adapter single-strand oligonucleotide (LASSO) probes.
Hopkins' Geoffrey Ling discusses the promise of genomic vaccines at Scientific American.
At the WIN Symposium, a Merck executive detailed how data from a basket study led to the first pan-cancer, biomarker-informed cancer drug.
In 86 pretreated cancer patients with mismatch repair deficiency, researchers saw objective response rates exceeding 50 percent after anti-PD-1 immunotherapy.
Qiagen will use NGS to develop gene expression profiles related to BMS immuno-oncology therapies; and the company has licensed IO therapy response biomarkers from JHU.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.